SELLAS Life Sciences Group, Inc. SEC Filings

SELLAS Life Sciences Group, Inc. updated executive compensation arrangements related to severance and change of control protection. The company amended CEO Dr. Angelos Stergiou’s employment agreement so that certain change of control severance payments will be made in a lump sum, with all other terms unchanged.

SELLAS also entered into amended and restated severance and change of control letter agreements with CFO John Burns and Chief Development Officer Dr. Dragan Cicic. Outside a change of control, each may receive nine months of base salary, a pro rata target bonus, and up to nine months of COBRA reimbursement if terminated without Cause or resigning for Good Reason. If such a termination occurs within the defined change of control period, each may receive lump sum payments equal to 15 months of base salary, a full target bonus, up to 18 months of COBRA reimbursement, and full vesting of unvested equity awards, subject to signing a separation and general release.

SELLAS Life Sciences Group, Inc. reported the results of its Annual Meeting of Stockholders held on June 16, 2026. A total of 115,511,771 shares, representing approximately 62.59% of outstanding common stock, were present in person or by proxy, establishing a valid quorum.

Stockholders re-elected Class I directors Robert Van Nostrand and Jane Wasman to serve until the 2029 Annual Meeting, ratified Baker Tilly US, LLP as independent auditor for the year ending December 31, 2026, and approved an amendment to the 2023 Equity Incentive Plan to add 20,000,000 shares. They also approved the advisory vote on executive compensation and an adjournment proposal to solicit additional proxies if needed.

Stergiou Angelos M. reported acquisition or exercise transactions in this Form 4 filing.

SELLAS Life Sciences Group reported that President and CEO Angelos M. Stergiou received a grant of 1,065,000 restricted stock units on June 16, 2026. These RSUs vest 25% on December 1, 2026 and 25% on each December 1 thereafter, subject to continued service, bringing his direct holdings to 1,759,183 shares.

SELLAS Life Sciences Group, Inc. provides an update on its cash position and share count. The company had $107.1 million in cash and cash equivalents as of March 31, 2026. In April and May 2026, it received about $28.7 million from the exercise of common stock warrants, adding to its liquidity.

As of June 2, 2026, SELLAS had 196,632,574 shares of common stock outstanding, giving investors a clearer picture of the current capital structure.

SELLAS Life Sciences Group, Inc. reported a first quarter 2026 net loss of $8.4 million, or $0.05 per share, wider than the $5.8 million loss, or $0.07 per share, a year earlier. Higher research and development expenses of $5.1 million and general and administrative expenses of $4.1 million drove the increase as the company invested in clinical programs and regulatory preparation.

Cash and cash equivalents rose to $107.1 million as of March 31, 2026, with an additional $7.5 million received in the second quarter from warrant exercises. SELLAS highlighted progress in its pivotal Phase 3 REGAL trial of GPS in acute myeloid leukemia, with 78 of 80 required events reached as of May 11, 2026, and ongoing dosing in a Phase 2 trial of SLS009 in newly diagnosed AML. The company also put in place an at-the-market equity offering program allowing up to $150 million in future capital raises.

SELLAS Life Sciences Group, Inc. reported a net loss of $8.4 million for the quarter ended March 31, 2026, as it continues late-stage oncology drug development. Operating expenses rose to $9.3 million, driven by higher GPS manufacturing and regulatory work and increased legal and public company costs.

Cash and cash equivalents increased to $107.1 million, boosted by $44.1 million from the exercise of 28.2 million warrants during the quarter, plus a further $7.5 million from warrant exercises after March 31. Management believes this liquidity will fund planned operations for at least twelve months and has also put a $150 million at-the-market equity program in place.

The company is advancing two key programs: the Phase 3 REGAL trial of GPS in acute myeloid leukemia, approaching its final overall-survival analysis, and a randomized Phase 2 trial of SLS009 in newly diagnosed AML following positive Phase 2a results in relapsed/refractory AML. SELLAS also highlights multiple FDA orphan and rare pediatric disease designations and an ongoing arbitration with 3D Medicines over GPS milestones.

SELLAS LIFE SCIENCES GROUP INC ownership update: BlackRock, Inc. reports beneficial ownership of 12,136,331 shares, representing 6.8% of common stock. The filing attributes sole voting power for 11,966,938 shares and sole dispositive power for 12,136,331 shares, reported by a Managing Director.

SELLAS Life Sciences Group, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 16, 2026 at 8:30 a.m. Eastern Time. The meeting will be held online only via live webcast at www.virtualshareholdermeeting.com/SLS2026.

Stockholders will vote on five proposals, including electing two Class I directors to terms ending in 2029, ratifying Baker Tilly US, LLP as independent registered public accounting firm for 2026, and approving an amendment to the 2023 Equity Plan to increase shares authorized for issuance by 20,000,000. They will also cast a non-binding advisory vote on executive compensation and consider approval of any adjournment or postponement of the meeting if needed to secure enough proxies or establish a quorum.

Holders of SELLAS common stock at the close of business on April 21, 2026, when 184,532,574 shares were outstanding, are entitled to one vote per share. The board recommends voting “FOR” all five proposals and outlines detailed governance practices, committee structures, ownership guidelines, and 2025 executive pay, including total 2025 compensation of $1,877,810 for the Chief Executive Officer.